← Back to Clinical Trials
Recruiting NCT07519629

NCT07519629 Training Caregivers to Teach Vocabulary to Children With Language Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07519629
Status Recruiting
Phase
Sponsor Northern Arizona University
Condition Developmental Language Disorder
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2026-02-23
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
Robust vocabulary intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 64 participants in total. It began in 2026-02-23 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine whether Spanish-speaking caregivers can learn to teach science vocabulary to their children with the use and educational app and a short training video with target words. The children will take language, speech, and hearing tests, as well as science and vocabulary pretests with a speech-language pathologist. You will be asked to answer some questions about your language use in the house and other places. If you and your child qualify for the study, the researcher will randomly place you a group to 1) use the app, or 2) use books. Since you are chosen at random, there is no way of knowing which group you and your child will be in before you start. Participants will take part in an 11-week study (3 weeks of testing at the beginning, middle, and end of study, and 8 weeks of intervention). The testing will be conducted in a place that is comfortable for your child (home, school, university clinic). The intervention can be done at home (researchers will not be present for this part of the study, but we will be available to support you or answer questions). We want you to play (group 1) or read (group 2) with your child two times a week (\~30 minutes) and send the audio recording of your interaction to our researchers.

Eligibility Criteria

Inclusion Criteria: Children: * age (4-6) and not have completed kindergarten prior to pretesting * pass a hearing screening to rule out hearing loss as a cause for language impairment * speak Spanish at least 50% of their day reported in BIOS * have a confirmed diagnosis of DLD via the BESA * not have a diagnosis of intellectual disability via Matrices subtest or social communication disorder via Social Communication Questionnaire * be able to speak with at least 3-word utterances Caregivers: * have access to a smart phone * spend time with the child participant daily * speak fluent Spanish Exclusion Criteria: \-

Contact & Investigator

Central Contact

Lindsey A Hiebert, Ph.D.

✉ Lindsey.Hiebert@nau.edu

📞 928-523-2109

Frequently Asked Questions

Who can join the NCT07519629 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 6 Years, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07519629 currently recruiting?

Yes, NCT07519629 is actively recruiting participants. Contact the research team at Lindsey.Hiebert@nau.edu for enrollment information.

Where is the NCT07519629 trial being conducted?

This trial is being conducted at Flagstaff, United States.

Who is sponsoring the NCT07519629 clinical trial?

NCT07519629 is sponsored by Northern Arizona University. The trial plans to enroll 64 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology